Choroidal thickness after intravitreal ranibizumab injections for choroidal neovascularization

Clinical Ophthalmology

Volumn 6, Issue 1, 2012, Pages 837-844

  Ellabban, Abdallah A ^a   Tsujikawa, Akitaka ^a   Ogino, Ken ^a   Ooto, Sotaro ^a   Yamashiro, Kenji ^a   Oishi, Akio ^a   Yoshimura, Nagahisa ^a  

^a KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Choroidal thickness; Optical coherence tomography; Ranibizumab

Indexed keywords

RANIBIZUMAB;

AGED; ARTICLE; CHOROIDAL THICKNESS; CLINICAL TRIAL; DISEASE ASSOCIATION; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MYOPIA; OPTICAL COHERENCE TOMOGRAPHY; OUTCOME ASSESSMENT; POLYPOIDAL CHOROIDAL VASCULOPATHY; PROSPECTIVE STUDY; RETINA FLUORESCEIN ANGIOGRAPHY; RETINA MACULA AGE RELATED DEGENERATION; RETINAL THICKNESS; SENSORY SYSTEM PARAMETERS; SUBRETINAL NEOVASCULARIZATION; TREATMENT DURATION; VISUAL ACUITY; VISUAL SYSTEM PARAMETERS;

EID: 84863487702     PISSN: 11775467     EISSN: 11775483     Source Type: Journal    
DOI: 10.2147/OPTH.S30907     Document Type: Article

References (48)

1. Chen Y, Wiesmann C, Fuh G, etal. Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen. J Mol Biol. 1999;293(4):865-881.
2. Ferrara N, Damico L, Shams N, Lowman H, Kim R. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina. 2006;26(8):859-870.
3. Miller JW, Adamis AP, Shima DT, etal. Vascular endothelial growth factor/vascular permeability factor is temporally and spatially correlated with ocular angiogenesis in a primate model. Am J Pathol. 1994;145(3): 574-584.
4. Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011;364(20):1897-1908.
5. Rosenfeld PJ, Brown DM, Heier JS, etal. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14): 1419-1431.
6. Brown DM, Kaiser PK, Michels M, etal. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1432-1444.
7. Mitchell P, Korobelnik JF, Lanzetta P, etal. Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trials. Br J Ophthalmol. 2000;94(1):2-13.
8. Mendrinos E, Mangioris G, Papadopoulou D, Donati G, Pournaras C. One year results of the effect of intravitreal ranibizumab on the retinal arteriolar diameter in patients with neovascular age-related macular degeneration. Invest Ophthalmol Vis Sci. Forthcoming.
9. Claffey KP, Robinson GS. Regulation of VEGF/VPF expression in tumor cells: consequences for tumor growth and metastasis. Cancer Metastasis Rev. 1996;15(2):165-176.
10. Nishijima K, Ng YS, Zhong L, etal. Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury. Am J Pathol. 2007;171(1):53-67.
11. Blaauwgeers HG, Holtkamp GM, Rutten H, etal. Polarized vascular endothelial growth factor secretion by human retinal pigment epithelium and localization of vascular endothelial growth factor receptors on the inner choriocapillaris. Evidence for a trophic paracrine relation. Am J Pathol. 1999;155(2):421-428.
12. Pournaras CJ, Rungger-Brandle E, Riva CE, Hardarson SH, Stefansson E. Regulation of retinal blood flow in health and disease. Prog Retin Eye Res. 2008;27(3):284-330.
13. Ferrara N. Vascular endothelial growth factor and the regulation of angiogenesis. Recent Prog Horm Res. 2000;55:15-35.
14. Linsenmeier RA, Padnick-Silver L. Metabolic dependence of photoreceptors on the choroid in the normal and detached retina. Invest Ophthalmol Vis Sci. 2000;41(10):3117-3123.
15. Nickla DL, Wallman J. The multifunctional choroid. Prog Retin Eye Res. 2010;29(2):144-168.
16. Spaide RF, Koizumi H, Pozzoni MC. Enhanced depth imaging spectral-domain optical coherence tomography. Am J Ophthalmol. 2008;146(4): 496-500.
17. Fong AH, Li KK, Wong D. Choroidal evaluation using enhanced depth imaging spectral-domain optical coherence tomography in Vogt-Koyanagi-Harada disease. Retina. 2011;31(3):502-509.
18. Margolis R, Spaide RF. A pilot study of enhanced depth imaging optical coherence tomography of the choroid in normal eyes. Am J Ophthalmol. 2009;147(5):811-815.
19. Reibaldi M, Boscia F, Avitabile T, etal. Enhanced depth imaging optical coherence tomography of the choroid in idiopathic macular hole: a cross-sectional prospective study. Am J Ophthalmol. 2011;151(1):112-117.
20. Spaide RF. Age-related choroidal atrophy. Am J Ophthalmol. 2009; 147(5):801-810.
21. Yeoh J, Rahman W, Chen F, etal. Choroidal imaging in inherited retinal disease using the technique of enhanced depth imaging optical coherence tomography. Graefes Arch Clin Exp Ophthalmol. 2010;248(12): 1719-1728.
22. Blackburn J, McGwin G Jr. Enhanced depth imaging optical coherence tomography of the choroid in idiopathic macular hole. Am J Ophthalmol. 2011;151(3):560-561.
23. Chung SE, Kang SW, Lee JH, Kim YT. Choroidal thickness in polypoidal choroidal vasculopathy and exudative age-related macular degeneration. Ophthalmology. 2011;118(5):840-845.
24. Koizumi H, Yamagishi T, Yamazaki T, Kawasaki R, Kinoshita S. Subfoveal choroidal thickness in typical age-related macular degeneration and polypoidal choroidal vasculopathy. Graefes Arch Clin Exp Ophthalmol. 2011;249(8):1123-1128.
25. Manjunath V, Goren J, Fujimoto JG, Duker JS. Analysis of choroidal thickness in age-related macular degeneration using spectral-domain optical coherence tomography. Am J Ophthalmol. 2011;152(4): 663-668.
26. Maruko I, Iida T, Sugano Y, Saito M, Sekiryu T. Subfoveal retinal and choroidal thickness after verteporfin photodynamic therapy for polypoidal choroidal vasculopathy. Am J Ophthalmol. 2011;151(4):594-603.
27. Maruko I, Iida T, Sugano Y, Ojima A, Ogasawara M, Spaide RF. Subfoveal choroidal thickness after treatment of central serous chorioretinopathy. Ophthalmology. 2010;117(9):1792-1799.
28. Imamura Y, Fujiwara T, Margolis R, Spaide RF. Enhanced depth imaging optical coherence tomography of the choroid in central serous chorioretinopathy. Retina. 2009;29(10):1469-1473.
29. Fujiwara T, Imamura Y, Margolis R, Slakter JS, Spaide RF. Enhanced depth imaging optical coherence tomography of the choroid in highly myopic eyes. Am J Ophthalmol. 2009;148(3):445-450.
30. Ikuno Y, Tano Y. Retinal and choroidal biometry in highly myopic eyes with spectral-domain optical coherence tomography. Invest Ophthalmol Vis Sci. 2009;50(8):3876-3880.
31. Ikuno Y, Jo Y, Hamasaki T, Tano Y. Ocular risk factors for choroidal neovascularization in pathologic myopia. Invest Ophthalmol Vis Sci. 2010;51(7):3721-3725.
32. Tilton RG, Chang KC, LeJeune WS, Stephan CC, Brock TA, Williamson JR. Role for nitric oxide in the hyperpermeability and hemodynamic changes induced by intravenous VEGF. Invest Ophthalmol Vis Sci. 1999;40(3):689-696.
33. Ku DD, Zaleski JK, Liu S, Brock TA. Vascular endothelial growth factor induces EDRF-dependent relaxation in coronary arteries. Am J Physiol. 1993;265(2 Pt 2):H586-H592.
34. Maruko I, Iida T, Sugano Y, etal. Subfoveal choroidal thickness after treatment of Vogt-Koyanagi-Harada disease. Retina. 2011;31(3): 510-517.
35. Imamura Y, Iida T, Maruko I, Zweifel SA, Spaide RF. Enhanced depth imaging optical coherence tomography of the sclera in dome-shaped macula. Am J Ophthalmol. 2011;151(2):297-302.
36. Wood A, Binns A, Margrain T, etal. Retinal and choroidal thickness in early age-related macular degeneration. Am J Ophthalmol. 2011;152(6):1030-1038.
37. Sadda S. Effect of anti-VEGF therapy on choroidal thickness in patients with neovascular age-related macular degeneration. Paper presented at: The 29th Annual Meeting of the American Society of Retina Specialists, Boston, NE, August 20-24, 2011.
38. Koizumi H, Yamazaki T, Yamagisgi T, Kinoshitra S. Subfoveal choroidal thickness after ranibizumab therapy for neovascular AMD: 12-month result. Poster session presented at: The 2011 Annual Meeting of American Academy of Ophthalmology, Orlando, FL, October 22-25, 2011.
39. Ikuno Y, Maruko I, Yasuno Y, etal. Reproducibility of retinal and choroidal thickness measurements in enhanced depth imaging and high-penetration optical coherence tomography. Invest Ophthalmol Vis Sci. 2011;52(8):5536-5540.
40. Rahman W, Chen FK, Yeoh J, Patel P, Tufail A, Da Cruz L. Repeatability of manual subfoveal choroidal thickness measurements in healthy subjects using the technique of enhanced depth imaging optical coherence tomography. Invest Ophthalmol Vis Sci. 2011;52(5):2267-2271.
41. Hirata M, Tsujikawa A, Matsumoto A, etal. Macular choroidal thickness and volume in normal subjects measured by swept-source optical coherence tomography. Invest Ophthalmol Vis Sci. 2011;52(8):4971-4978.
42. Ferrara N. Vascular endothelial growth factor: molecular and biological aspects. Curr Top Microbiol Immunol. 1999;237:1-30.
43. Papadopoulou DN, Mendrinos E, Mangioris G, Donati G, Pournaras CJ. Intravitreal ranibizumab may induce retinal arteriolar vasoconstriction in patients with neovascular age-related macular degeneration. Ophthalmology. 2009;116(9):1755-1761.
44. Soliman W, Vinten M, Sander B, etal. Optical coherence tomography and vessel diameter changes after intravitreal bevacizumab in diabetic macular oedema. Acta Ophthalmol. 2008;86(4):365-371.
45. Yokoyama K, Choshi T, Kimoto K, Shinoda K, Nakatsuka K. Retinal circulatory disturbances following intracameral injection of bevacizumab for neovascular glaucoma. Acta Ophthalmol. 2008;86(8): 927-928.
46. Kim KS, Chang HR, Song S. Ischaemic change after intravitreal bevacizumab (Avastin) injection for macular oedema secondary to non-ischaemic central retinal vein occlusion. Acta Ophthalmol. 2008;86(8):925-927.
47. Agawa T, Miura M, Ikuno Y, etal. Choroidal thickness measurement in healthy Japanese subjects by three-dimensional high-penetration optical coherence tomography. Graefes Arch Clin Exp Ophthalmol. 2011;249(10):1485-1492.
48. Esmaeelpour M, Povazay B, Hermann B, etal. Three-dimensional 1060-nm OCT: choroidal thickness maps in normal subjects and improved posterior segment visualization in cataract patients. Invest Ophthalmol Vis Sci. 2010;51(10):5260-5266.